ELOVL1-IN-1_product_DataBase

Bioactivity	ELOVL1-IN-1 is an ELOVL1 inhibitor extracted from patent WO2018107056A1, compound 87. ELOVL1-IN-1 can reduce very long chain fatty acid levels. ELOVL1-IN-1 can be used for the research of adrenoleukodystrophy (ALD)[1].
Target	ELOVL1
Invitro	ELOVL1-IN-1 (compound 87) (1 nM-10 μM; 48 h) reduces the the level of VLCFA, lysophosphatidylcholine (LPC) in adrenoleukodystrophy (ALD) patient fibroblasts and healthy human fibroblasts, ALD patient B‐lymphocytes, and human microglia[1].
In Vivo	ELOVL1-IN-1 (compound 87) reduces of a VLCFA level, specifically C26:0 LPC level in blood of ABCD1 knockout (KO) mice (0.5-64 mg/kg; p.o. once daily for 28 days), wild‐type (WT) rats (30-300 mg/kg; p.o. once daily for 7 days), and cynomolgous monkeys (30 mg/kg; p.o. once daily for 7 days)[1].
Name	ELOVL1-IN-1
CAS	2227482-41-7
Formula	C18H14F2N4O
Molar Mass	340.33
Appearance	Solid
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Reference	[1]. Charifson PS, et, al. 1,3-substitued pyrazole compounds useful for reduction of very long chain fatty acic levels. WO2018107056A1.

PeptideDB